Researchers at the University of California, Davis have developed a modular CRISPR activation platform that enables precise upregulation of the haploinsufficient gene FOXG1 to address neurodevelopmental disorders without DNA cleavage.

A mechanistic discovery linking amyloid beta (Aβ)-associated neurodegeneration with chronic pain after peripheral nerve injury, revealing Aβ as a novel therapeutic target.

Researchers at the University of California, Davis have developed a modular, containerized cooling solution designed to support high‑density computing environments such as data centers and AI clusters. The system combines efficient air‑to‑liquid heat exchange, integrated energy storage options, and intelligent controls to reduce operating costs, improve deployment speed, and enhance system uptime.

Brief description not available

Brief description not available

RNA-guided systems mediate diverse functions ranging from mobile genetic element propagation to adaptive immunity. These systems comprise proteins that use guide RNAs bearing sequence complementarity to nucleic acid substrates, facilitating programmable recognition of different substrates by the same protein or enzyme. In RNA-guided systems known to date, one or two continuous segments in the guideRNA determines target specificity and can be altered to direct the system to a new target, including genomic DNA in eukaryotic cells. However, there are constraints to such systems, e.g., protein size and the need for a protospacer adjacent motif (PAM) in target DNA. However, there is a need for nucleic acid guided systems that overcome constraints of known systems, such as protein size or protospacer adjacent motif.UC Berkeley researchers have developed a programmable RNA-guided nucleic acid targeting platform termed the Viral Interference Programmable Repeat (VIPR) system. The system employs a repeat-based guide RNA architecture and an associated targeting protein to direct sequence-specific recognition of nucleic acid substrates. Target specificity is programmable through modification of selected guide regions, enabling adaptable targeting of DNA or RNA substrates across different biological contexts, including cellular and viral genetic material.

The aim of this work is to target the production of age-specific production of hyperactive platelets as a therapeutic platform to control clot formation that causes thrombosis, stroke, heart attacks, and other cardiovascular disease, as well as platelet overproduction disorders such as essential thrombocytosis. In particular, this effort specifically targets cells that have progressed down an age-specific differentiation pathway. These age specific platelets are hyperactive relative to platelets from younger progenitor cells. These older platelet progenitor cells have been characterized molecularly and functionally characterization and can be targeted using pharmacological, antibody-based, cell based or gene therapy based strategies to control clot formation and platelet activity and numbers.

Brief description not available